Research
Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction
Christopher Labos, Kaberi Dasgupta, Hacene Nedjar, Gustavo Turecki and Elham Rahme
CMAJ November 08, 2011 183 (16) 1835-1843; DOI: https://doi.org/10.1503/cmaj.100912
Christopher Labos
MD CM
Kaberi Dasgupta
MD MSc
Hacene Nedjar
MSc
Gustavo Turecki
MD PhD
Elham Rahme
PhD
Data supplements
Online Appendix
Files in this Data Supplement:
Related Articles
- Juurlink, D. N. (2011). Antidepressants, antiplatelets and bleeding: One more thing to worry about?. CMAJ, 183(16), 1819-1820. Accessed April 20, 2024. https://doi.org/10.1503/cmaj.111576.
In this issue
Article tools
Respond to this article
Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction
Christopher Labos, Kaberi Dasgupta, Hacene Nedjar, Gustavo Turecki, Elham Rahme
CMAJ Nov 2011, 183 (16) 1835-1843; DOI: 10.1503/cmaj.100912
Jump to section
Related Articles
Cited By...
- Psychopharmacology and Cardiovascular Disease
- Neuroplasticity and behavioral effects of fluoxetine after experimental stroke
- Outcomes and Prognostic Impact of Prophylactic Oral Anticoagulation in Anterior ST-Segment Elevation Myocardial Infarction Patients With Left Ventricular Dysfunction
- Predictors for Recurrent Primary Intracerebral Hemorrhage: A Retrospective Population-based Study
- Fluoxetine Is a Potent Inhibitor of Coxsackievirus Replication
- Excess Bleeding Risk in Patients Taking SSRIs plus Antiplatelet Drugs
- Antidepressants, antiplatelets and bleeding: One more thing to worry about?